Pharmacokinetics/pharmacodynamics of a β-lactam and β-lactamase inhibitor combination: a novel approach for aztreonam/avibactam

Activities of Ceftazidime and Avibactam against β-Lactamase-Producing Enterobacteriaceae in a Hollow-Fiber Pharmacodynamic Model

(2014) Ken Coleman et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

New β-Lactamase Inhibitors: a Therapeutic Renaissance in an MDR World

(2013) Sarah M. Drawz et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Ceftolozane in anIn VitroInfection Model

(2013) Brian VanScoy et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Human Simulated Studies of Aztreonam and Aztreonam-Avibactam To Evaluate Activity against Challenging Gram-Negative Organisms, Including Metallo-β-Lactamase Producers

(2013) Jared L. Crandon et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacological Basis of β-Lactamase Inhibitor Therapeutics: Tazobactam in Combination with Ceftolozane

(2013) Brian VanScoy et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Single- and Multiple-Dose Study To Determine the Safety, Tolerability, and Pharmacokinetics of Ceftaroline Fosamil in Combination with Avibactam in Healthy Subjects

(2013) Todd A. Riccobene et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

ComparativeIn VitroandIn VivoEfficacies of Human Simulated Doses of Ceftazidime and Ceftazidime-Avibactam against Pseudomonas aeruginosa

(2012) Jared L. Crandon et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Novel Modeling Framework To Guide Design of Optimal Dosing Strategies for β-Lactamase Inhibitors

(2012) Pratik Bhagunde et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VivoActivities of Ceftolozane, a New Cephalosporin, with and without Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, Including Strains with Extended-Spectrum β-Lactamases, in the Thighs of Neutropenic Mice

(2012) W. A. Craig et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Characterization of  -lactamase and porin mutants of Enterobacteriaceae selected with ceftaroline + avibactam (NXL104)

(2012) D. M. Livermore et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Pharmacodynamics of β-Lactamase Inhibition by NXL104 in Combination with Ceftaroline: Examining Organisms with Multiple Types of β-Lactamases

(2011) Arnold Louie et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacodynamics of TD-1792, a Novel Glycopeptide-Cephalosporin Heterodimer Antibiotic Used against Gram-Positive Bacteria, in a Neutropenic Murine Thigh Model

(2011) Sharath S. Hegde et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach

(2011) J.W. Mouton et al.   CLINICAL MICROBIOLOGY AND INFECTION

Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors

(2011) Ken Coleman   CURRENT OPINION IN MICROBIOLOGY

Optimizing dosage to prevent emergence of resistance – lessons from in vitro models

(2011) Renu Singh et al.   CURRENT OPINION IN PHARMACOLOGY

Does broad-spectrum  -lactam resistance due to NDM-1 herald the end of the antibiotic era for treatment of infections caused by Gram-negative bacteria?

(2011) P. Nordmann et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Metallo-β-lactamases: a last frontier for β-lactams?

(2011) Giuseppe Cornaglia et al.   LANCET INFECTIOUS DISEASES

The emerging NDM carbapenemases

(2011) Patrice Nordmann et al.   TRENDS IN MICROBIOLOGY

Characterization of a New Metallo- -Lactamase Gene, blaNDM-1, and a Novel Erythromycin Esterase Gene Carried on a Unique Genetic Structure in Klebsiella pneumoniae Sequence Type 14 from India

(2009) D. Yong et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY